

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Jeffrey R. STINSON et al.

Serial No. 09/215,163

Filed: December 18, 1998

For: HUMANIZED MONOCLONAL ANTIBODIES
THAT PROTECT AGAINST SHIGA TOXIN
INDUCED DISEASE



Group Art Unit: 1615

Examiner: V. Ryan

#6/Election
3/19/00
JW

Assistant Commissioner for Patents
Washington, D.C. 20231

MAR 15 2000

MAR 15 2000
TECH CENTER 1600/2900

Sir:

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

In a restriction requirement dated February 14, 2000, the Examiner required restriction under 35 U.S.C. § 121 between the claims of Group I (Claims 1-10, 13-20, 23, 26 and 29); Group II (Claims 11, 12, 21, and 22); and Group III (Claims 24, 25, 27, 28, 30 and 31). Applicants provisionally elect to prosecute Group I (Claims 1-10, 13-20, 23, 26 and 29), drawn to humanized monoclonal antibody, with traverse. Additionally, Applicants provisionally elect Species B, directed to monoclonal antibody that binds to Shiga toxin type 2, with traverse.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: Charles E. Van Horn #40266
for Jean B. Fordis
Reg. No. 32,984

Date: March 14, 2000

TECH CENTER 1600/2900
MAR 15 2000

RECEIVED
MAR 16 2000
LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, D. C. 20005
202-408-4000